| 151 | LEGNLegend Biotech Corp |
1 mld USD |
-28,8% |
2025 |
| 152 | TNDMTandem Diabetes Care Inc |
1 mld USD |
-20,2% |
2025 |
| 153 | INNVInnovAge Holding Corp. |
989,7 mln USD |
-0,3% |
2026 |
| 154 | GHGuardant Health, Inc. |
982 mln USD |
-42,4% |
2025 |
| 155 | MDGLMadrigal Pharmaceuticals, Inc. |
958,4 mln USD |
-30,1% |
2025 |
| 156 | PNTGPennant Group, Inc. |
947,7 mln USD |
3,1% |
2025 |
| 157 | IONSIonis Pharmaceuticals Inc |
943,7 mln USD |
-40,4% |
2025 |
| 158 | USNAUsana Health Sciences Inc |
925,3 mln USD |
1,2% |
2025 |
| 159 | TLRYTilray Brands, Inc. |
915,5 mln USD |
-13,3% |
2026 |
| 160 | INSPInspire Medical Systems, Inc. |
912 mln USD |
15,9% |
2025 |
| 161 | ANIPAni Pharmaceuticals Inc |
883,4 mln USD |
8,9% |
2025 |
| 162 | BCRXBiocryst Pharmaceuticals Inc |
874,8 mln USD |
30,2% |
2025 |
| 163 | WRBYWarby Parker Inc. |
871,9 mln USD |
0,2% |
2025 |
| 164 | NEOGNeogen Corp |
870,4 mln USD |
-0,9% |
2026 |
| 165 | HRMYHarmony Biosciences Holdings, Inc. |
868,5 mln USD |
18,3% |
2025 |
| 166 | ARWRArrowhead Pharmaceuticals, Inc. |
829,4 mln USD |
-0,2% |
2025 |
| 167 | MYGNMyriad Genetics Inc |
824,5 mln USD |
-44,4% |
2025 |
| 168 | OFIXOrthofix Medical Inc. |
822,3 mln USD |
-11,2% |
2025 |
| 169 | CAICaris Life Sciences, Inc. |
812 mln USD |
-8,4% |
2025 |
| 170 | TLXTelix Pharmaceuticals Ltd |
803,8 mln USD |
-0,9% |
2025 |
| 171 | USPHU S Physical Therapy Inc |
781 mln USD |
5,1% |
2025 |
| 172 | COLLCollegium Pharmaceutical, Inc |
780,6 mln USD |
8,1% |
2025 |
| 173 | ATECAlphatec Holdings, Inc. |
764,2 mln USD |
-18,8% |
2025 |
| 174 | CORTCorcept Therapeutics Inc |
761,4 mln USD |
13,1% |
2025 |
| 175 | IRTCiRhythm Holdings, Inc. |
747,1 mln USD |
-6,0% |
2025 |
| 176 | EBSEmergent BioSolutions Inc. |
742,9 mln USD |
7,1% |
2025 |
| 177 | RGENRepligen Corp |
738,3 mln USD |
6,6% |
2025 |
| 178 | NEONeogenomics Inc |
727,3 mln USD |
-14,9% |
2025 |
| 179 | PCRXPacira BioSciences, Inc. |
726,4 mln USD |
1,0% |
2025 |
| 180 | AMPHAmphastar Pharmaceuticals, Inc. |
719,9 mln USD |
13,6% |
2025 |
| 181 | SUPNSupernus Pharmaceuticals, Inc. |
719 mln USD |
-5,4% |
2025 |
| 182 | AVNSAvanos Medical, Inc. |
701,2 mln USD |
-10,4% |
2025 |
| 183 | KNSAKiniksa Pharmaceuticals International, plc |
677,6 mln USD |
8,7% |
2025 |
| 184 | RAREUltragenyx Pharmaceutical Inc. |
673 mln USD |
-85,4% |
2025 |
| 185 | CRLBFCresco Labs Inc. |
655,8 mln USD |
-20,6% |
2025 |
| 186 | NVCRNovoCure Ltd |
655,4 mln USD |
-20,8% |
2025 |
| 187 | AXSMAxsome Therapeutics, Inc. |
638,5 mln USD |
-28,7% |
2025 |
| 188 | TGTXTG Therapeutics, Inc. |
616,3 mln USD |
72,6% |
2025 |
| 189 | CDRECadre Holdings, Inc. |
610,3 mln USD |
7,2% |
2025 |
| 190 | OPKOpko Health, Inc. |
606,9 mln USD |
-37,2% |
2025 |
| 191 | INSMINSMED Inc |
606,4 mln USD |
-210,5% |
2025 |
| 192 | TMDXTransMedics Group, Inc. |
605,5 mln USD |
31,4% |
2025 |
| 193 | UFPTUfp Technologies Inc |
602,8 mln USD |
11,3% |
2025 |
| 194 | ALVOAlvotech |
586,3 mln USD |
4,8% |
2025 |
| 195 | BVSBioventus Inc. |
568,1 mln USD |
4,0% |
2025 |
| 196 | RLXRLX Technology Inc. |
566,1 mln USD |
23,3% |
2025 |
| 197 | ORGOOrganogenesis Holdings Inc. |
564,2 mln USD |
6,6% |
2025 |
| 198 | HCMHUTCHMED (China) Ltd |
548,5 mln USD |
83,3% |
2025 |
| 199 | ATRCAtriCure, Inc. |
534,5 mln USD |
-2,1% |
2025 |
| 200 | MIRMMirum Pharmaceuticals, Inc. |
521,3 mln USD |
-4,5% |
2025 |